Chemotherapy for germ cell cancer;Chemotherapie von keimzelltumoren

Urologe - Ausgabe A

Volumn 43, Issue 12, 2004, Pages 1507-1513

  Beyer, J ^a   Bokemeyer, C ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Chemotherapy; Germ cell tumor; Guideline; Supportive care; Testicular cancer

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; OXALIPLATIN; PACLITAXEL; VINBLASTINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CONSENSUS; DOSE RESPONSE; DRUG EFFICACY; GERM CELL TUMOR; HUMAN; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG THERAPY; EUROPE; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PALLIATIVE CARE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 12144279216     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-004-0704-5     Document Type: Article

References (23)

1. Albers P, Dommer K, Muller SC (1998) Hodentumoren. Todesfälle und Rezidive nach inadäquater Therapie. Urologe A 37: 625-628
2. Beyer J, Rick O, Siegert W (2001) Salvage chemotherapy in relapsed germ cell tumors. World J Urol 29: 90-93
3. Beyer J, Stenning S, Gerl A, Fossa S, Siegert W (2002) High-dose vs. conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 13: 599-605
4. Bokemeyer C, Hartmann JT, Kuczyk MA et al. (1998) Recent strategies for the use of paclitaxel in the treatment of urological malignancies. World J Urol 16: 155-162
5. Bokemeyer C, Kollmannsberger C, Meisner C et al. (1999) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 17: 3450-3456
6. Collette L, Sylvester RJ, Stenning SP et al. (1999) Impact of the treating institution on survival of patients with "poor prognosis" metastatic nonseminoma. J Natl Cancer Inst 91: 839-846
7. Fossa SD, Kaye SB, Mead GM et al. (1998) Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancies. J Clin Oncol 16: 716-724
8. Fossa SD, Stenning SP Gerl A et al. (1999) Prognostic factors in patients progressing after platinum-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80: 1392-1399
9. Hartmann JT, Classen J, Bokemeyer C (2003) Chemotherapie bei Keimzelltumoren mit intermediärer und schlechter Prognose. Onkologe 9: 985-391
10. International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594-603
11. Jakob A, Kollmannsberger C, Kanz L, Bokemeyer C (1998) Spättoxizität nach Chemotherapie maligner Hodentumoren. Urologe A 37: 635-647
12. Kollmannsberger C, Nichols C, Meisner C, Mayer F, Kanz L, Bokemeyer C (2000) Identification of prognostic subgroups among patients with metastatic,IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol 11: 1115-1120
13. Krege S, Schmoll HJ, Souchon R (2001) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren. Urologe A 40: 137-147
14. Link H, Bokemeyer C, Feyer P (Hrsg) (2004) Supportivtherapie bei malignen Erkrankungen. Deutscher Ärzte-Verlag, Köln
15. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16: 2500-2504
16. Mayer F, Kollmannsberger C, Bokemeyer C (2003) Behandlung von Patienten mit cisplatin-refraktären Keimzelltumoren. Onkologe 9: 1004-1008
17. Motzer RB, Sheinfeld J, Mazumdar M et al. (2000) Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18: 2413-2418
18. Nichols CR, Catalano PJ, Crawford ED et al. (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an eastern cooperative oncology group, southwest oncology group, and cancer and leukemia group B study. J Clin Oncol 16: 1287-1293
19. Rick O, Kollmannsberger C, Hartmann JT et al. (2004) The role of high-dose chemotherapy in relapsed germ cell tumors. World J Urol 22: 25-32
20. Schlimok G (Hrsg) (1999) Supportivtherapie in der Hämatologie/ Onkologie. Unimed, Bremen
21. Schmoll H-J, Kollmannsberger C, Metzner B et al. (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21: 4083-4091
22. Schmoll HJ, Souchon R, Krege S et al. (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (in press)
23. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ (1987) Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 316: 1435-1440